Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Positron Emission Tomography01:29

Positron Emission Tomography

7.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.9K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

705
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
705

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Case Report: Cardiac metastasis from urothelial carcinoma with predominant squamous differentiation in a young woman: first reported case treated with enfortumab vedotin plus pembrolizumab.

Frontiers in oncology·2026
Same author

Quantitative accuracy of <sup>177</sup>Lu SPECT/CT imaging using ring-shaped CZT versus dual-head NaI systems.

EJNMMI physics·2026
Same author

Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

<sup>211</sup>At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

European journal of nuclear medicine and molecular imaging·2026
Same author

Preoperative Assessment of Peritoneal Carcinomatosis with [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT: Agreement with Surgicopathologic PCI and Comparison with MRI and [<sup>18</sup>F]FDG PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

FAP-targeted PET Imaging in Peritoneal Carcinomatosis.

The British journal of radiology·2026

相关实验视频

Updated: Mar 14, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K

对于[177Lu]Lu-PSMA响应评估使用定量RECIP 1.0的SPECT与PET.

Mutaz Kassas1, Ayoub Jaafari1, Qaid Ahmed Shagera1,2

  • 1Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
|March 12, 2026
PubMed
概括

循环2 SPECT/CT 提供与PSMA PET/CT 实质性的协议,用于评估接受放射性药物治疗的转移性割抵抗性前列腺癌患者的治疗反应. 这种成像模式为整体存活率提供了可比的预后准确性,支持其用于早期反应评估.

关键词:
卢-PSMAMA 的意思是在RECIP中使用RECIP.在SPECT/CT测试中,前列腺癌是前列腺癌.响应评估 响应评估 响应评估

更多相关视频

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.3K

相关实验视频

Last Updated: Mar 14, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.5K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.3K

科学领域:

  • 核医学就是核医学.
  • 在瘤学瘤学.
  • 放射性药物疗法是一种放射性药物疗法.

背景情况:

  • 前列腺特异性膜抗原 (PSMA) PET/CT对于监测转移性割抗性前列腺癌 (mCRPC) 放射性药物治疗 (RPT) 反应至关重要.
  • 常规的PSMA PET/CT使用受到访问和成本的限制,需要评估替代成像技术.
  • [177][Lu]Lu-PSMA RPT是对mCRPC的标准治疗方法,需要有效的反应监测.

研究的目的:

  • 为了比较循环2的响应状态和预后意义177Lu-PSMA SPECT/CT与PSMA PET/CT在接受RPT的mCRPC患者中的反应状态和预后意义.
  • 评估SPECT/CT与PET/CT相比的诊断一致性和预后准确性,以评估治疗反应.

主要方法:

  • 接受Lu-PSMA RPT的102名mCRPC患者在治疗后24小时接受了SPECT/CT,在基线和两次循环后接受了PSMA PET/CT.
  • 进行了视觉和定量分析,根据RECIP 1.0.0进行了病变细分和反应分类.
  • 使用考克斯危险比率和卡普兰-梅尔曲线分析了无进展生存率 (PFS) 和总生存率 (OS).

主要成果:

  • 循环2SPECT/CT显示与PSMA PET/CT在识别疾病进展方面存在实质性一致 (κ = 0.67),SPECT进展始终得到PET证实.
  • 这两种模式都确定了与显著更短的PFS和OS相关的进展性疾病.
  • 在PSMA PET/CT中,PFS的预后准确性更高 (C指数为0.66比0.57),但OS的预后准确性相似 (C指数为0.63比0.58).

结论:

  • 循环2 SPECT/CT 提供了与PSMA PET/CT 的实质性协议,用于 mCRPC 的Lu-PSMA RPT 中的响应评估.
  • SPECT/CT实现了可比的整体存活预后准确度,支持其用于早期治疗反应评估的实用性.
  • 这些发现表明,当PET/CT访问有限时,SPECT/CT是监测Lu-PSMA RPT反应的可行替代方案.